ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

ODAC Actions: Large Subset analysis Of CALGB Study Was Basis for BMS Taxol Application

September 24, 1999

ASCO Foundation Renamed

February 18, 2011

AIDS Drug Discovery Groups RFA Draws 20 Applications

May 9, 1986

Project Expands Group Studies To Community Oncologists.

March 10, 2000

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

April 27, 2007

NCI Grants: UT Southwestern, M.D. Anderson Win Lung Cancer SPORE

December 6, 1996